Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK’s HIV Drug in Focus
This week was ruled by FDA and EU approvals for new cancer therapies as well as line extensions of cancer drugs. These included EU approvals for Novartis’ NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J’s JNJ Imbruvica in combination with Roche’s RHHBY Rituxan for a rare cancer. The FDA also approved Merck’s MRK two new HIV medicines containing its investigational medicine, doravirine. […]